Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as correlates of protection. These immune markers were measured at the time of second vaccination and 4 weeks later, with...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilbert, Peter B., Montefiori, David C., McDermott, Adrian B., Fong, Youyi, Benkeser, David, Deng, Weiping, Zhou, Honghong, Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Flach, Britta, Lin, Bob C., O’Connell, Sarah, McDanal, Charlene, Eaton, Amanda, Sarzotti-Kelsoe, Marcella, Lu, Yiwen, Yu, Chenchen, Borate, Bhavesh, van der Laan, Lars W. P., Hejazi, Nima S., Huynh, Chuong, Miller, Jacqueline, El Sahly, Hana M., Baden, Lindsey R., Baron, Mira, De La Cruz, Luis, Gay, Cynthia, Kalams, Spyros, Kelley, Colleen F., Andrasik, Michele P., Kublin, James G., Corey, Lawrence, Neuzil, Kathleen M., Carpp, Lindsay N., Pajon, Rolando, Follmann, Dean, Donis, Ruben O., Koup, Richard A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017870/
https://www.ncbi.nlm.nih.gov/pubmed/34812653
http://dx.doi.org/10.1126/science.abm3425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017870/
https://www.ncbi.nlm.nih.gov/pubmed/34812653
http://dx.doi.org/10.1126/science.abm3425

Ejemplares similares